Immuno-Biological Laboratories Co., Ltd. (4570.T)
JPY 453.0
(2.03%)
JPY 453.0
(2.03%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 412.99 Million JPY | -11.82% |
| 2022 | 468.33 Million JPY | -6.13% |
| 2021 | 498.91 Million JPY | -15.13% |
| 2020 | 587.83 Million JPY | -32.82% |
| 2019 | 875 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 98 Million JPY | 5.92% |
| 2023 Q3 | 115.13 Million JPY | 16.98% |
| 2023 Q1 | 102.22 Million JPY | -16.96% |
| 2023 Q4 | 97.21 Million JPY | -15.56% |
| 2023 FY | 412.99 Million JPY | -11.82% |
| 2023 Q2 | 98.41 Million JPY | -3.72% |
| 2022 Q3 | 117.46 Million JPY | 0.88% |
| 2022 FY | 468.33 Million JPY | -6.13% |
| 2022 Q4 | 123.1 Million JPY | 4.8% |
| 2022 Q2 | 116.43 Million JPY | 0.0% |
| 2021 FY | 498.91 Million JPY | -15.13% |
| 2020 FY | 587.83 Million JPY | -32.82% |
| 2019 FY | 875 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | 67.848% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | 28.402% |
| GNI Group Ltd. | 9.32 Billion JPY | 95.57% |
| Linical Co., Ltd. | 2.7 Billion JPY | 84.733% |
| Trans Genic Inc. | 2.15 Billion JPY | 80.879% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | 72.304% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 86.552% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | 77.76% |
| AnGes, Inc. | 8.9 Billion JPY | 95.361% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | 56.208% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 97.848% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | 57.658% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | 83.915% |
| CanBas Co., Ltd. | 278 Million JPY | -48.558% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | 63.822% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | 77.283% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | 74.249% |
| Kidswell Bio Corporation | 2.37 Billion JPY | 82.604% |
| PeptiDream Inc. | 9.68 Billion JPY | 95.737% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | 78.935% |
| Ribomic Inc. | 1.1 Billion JPY | 62.649% |
| SanBio Company Limited | 4.53 Billion JPY | 90.901% |
| Healios K.K. | 3.48 Billion JPY | 88.156% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | 64.235% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | 69.052% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | 70.574% |
| StemRIM | 2.07 Billion JPY | 80.106% |
| CellSource Co., Ltd. | 1.96 Billion JPY | 78.967% |
| FunPep Company Limited | 313.82 Million JPY | -31.6% |
| Kringle Pharma, Inc. | 958.01 Million JPY | 56.891% |
| Stella Pharma Corporation | 963.98 Million JPY | 57.158% |
| TMS Co., Ltd. | 943.25 Million JPY | 56.216% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | 62.109% |
| Cuorips Inc. | 598.11 Million JPY | 30.952% |
| K Pharma,Inc. | 543.94 Million JPY | 24.075% |
| Takara Bio Inc. | 23.9 Billion JPY | 98.272% |
| ReproCELL Incorporated | 1.51 Billion JPY | 72.722% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | 65.119% |
| StemCell Institute Inc. | 1.16 Billion JPY | 64.462% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | 72.87% |
| CellSeed Inc. | 804.93 Million JPY | 48.692% |